Clinical Trials
17 trialsNCT06166836 2026-03-25
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Active not recruiting
NCT03207672 2026-03-03
Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Eisai Inc.
Phase 1 Active not recruiting
NCT05840224 2026-01-28
Study of GS-4528 in Adults With Solid Tumors
Gilead Sciences
Phase 1 Active not recruiting
NCT06932952 2026-01-16
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V.
Phase 1 Active not recruiting
NCT03875287 2026-01-12
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06631079 2026-01-08
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NEC Bio B.V
Phase 1/2 Active not recruiting
NCT06220318 2025-11-28
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting
NCT05119907 2025-11-17
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Gilead Sciences
Phase 2 Active not recruiting
NCT05627063 2025-10-20
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
Phase 1 Active not recruiting
NCT05642780 2025-10-14
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT05718557 2025-08-03
Study of PYX-106 in Solid Tumors
Pyxis Oncology, Inc
Phase 1 Active not recruiting
NCT02608385 2025-06-08
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
Phase 1 Active not recruiting
NCT05379946 2025-04-08
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
InventisBio Co., Ltd
Phase 1/2 Active not recruiting
NCT05580991 2025-02-13
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
Canwell Biotech Limited
Phase 1 Active not recruiting
NCT03839342 2025-02-03
BEAVER
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting
NCT03865082 2022-02-17
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
Phase 2 Active not recruiting